Top

Published in:

01-10-2013 | Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Potential Benefits of Rho-kinase Inhibition in Arterial Hypertension

Author: Olaf Grisk

Published in: Current Hypertension Reports | Issue 5/2013

Abstract

Arterial hypertension is a major health problem, accounting for 12 % of the global death rate. A large proportion of patients treated for high blood pressure do not reach target blood pressure values. The question arises if new antihypertensive drugs could improve present hypertension treatment. Rho-kinases (ROCKs) are ubiquitously expressed serine/threonine kinases and involved in a variety of cell functions. They contribute to the pathogenesis of human and experimental hypertension. Pharmacological ROCK inhibition has been shown to effectively lower blood pressure in patients and experimental animals. Progress has been made towards the understanding on how non-selective ROCK inhibitors lower arterial pressure and efforts are currently undertaken to develop ROCK inhibitors to improve their specificity and isoenzyme selectivity. If introduction of ROCK inhibitors for the treatment of high blood pressure can significantly advance currently available options of antihypertensive pharmacotherapy awaits further experimental and clinical research.

Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels. J Hypertens. 2006;24(3):413–22.PubMedCrossRef

Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–92. doi:10.1097/01.hjh.0000084751.37215.d2.PubMedCrossRef

Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens. 2006;24(3):423–30. doi:10.1097/01.hjh.0000209973.67746.f0.PubMedCrossRef

Mulvany MJ. Small artery remodelling in hypertension: causes, consequences and therapeutic implications. Med Biol Eng Comput. 2008;46(5):461–7. doi:10.1007/s11517-008-0305-3.PubMedCrossRef

Guyton AC. Blood pressure control–special role of the kidneys and body fluids. Science. 1991;252(5014):1813–6.PubMedCrossRef

Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R1001–18. doi:10.1152/ajpregu.90960.2008.PubMedCrossRef

Chalmers J, Arima H, Harrap S, Touyz RM, Park JB. Global survey of current practice in management of hypertension as reported by societies affiliated with the international society of hypertension. J Hypertens. 2013;31(5):1043–8. doi:10.1097/HJH.0b013e32835f7eef.PubMedCrossRef

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi:10.1136/bmj.b1665.PubMedCrossRef

Fletcher RD, Amdur RL, Kolodner R, McManus C, Jones R, Faselis C, et al. Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation. 2012;125(20):2462–8. doi:10.1161/CIRCULATIONAHA.111.029983.PubMedCrossRef

10.

Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126(17):2105–14. doi:10.1161/CIRCULATIONAHA.112.096156.PubMedCrossRef

11.

Mancia G. Blood pressure reduction and cardiovascular outcomes: past, present, and future. Am J Cardiol. 2007;100(3A):3J–9J. doi:10.1016/j.amjcard.2007.05.008.PubMedCrossRef

12.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26. doi:10.1161/CIRCULATIONAHA.108.189141.PubMedCrossRef

13.

Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42. doi:10.1161/CIRCULATIONAHA.111.068064.PubMedCrossRef

14.

Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50(1):17–24. doi:10.1097/FJC.0b013e318070d1bd.PubMedCrossRef

15.

• Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci: CMLS. 2010;67(2):171–7. doi:10.1007/s00018-009-0189-x. Provides an overview on isoenzyme selectivity of ROCK inhibitors.PubMedCrossRef

16.

Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98(3):322–34. doi:10.1161/01.RES.0000201960.04223.3c.PubMedCrossRef

17.

•• Wirth A. Rho kinase and hypertension. Biochim Biophys Acta. 2010;1802(12):1276–84. doi:10.1016/j.bbadis.2010.05.002. Provides a recent comprehensive overview on the regulation of ROCK activity, ROCK substrates and the role of ROCKs in vascular biology.PubMedCrossRef

18.

Nunes KP, Rigsby CS, Webb RC. RhoA/Rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci: CMLS. 2010;67(22):3823–36. doi:10.1007/s00018-010-0460-1.PubMedCrossRef

19.

Duess JW, Fujiwara N, Corcionivoschi N, Puri P, Thompson J. ROCK inhibitor (Y-27632) disrupts somitogenesis in chick embryos. Pediatr Surg Int. 2013;29(1):13–8. doi:10.1007/s00383-012-3202-7.PubMedCrossRef

20.

Phillips HM, Papoutsi T, Soenen H, Ybot-Gonzalez P, Henderson DJ, Chaudhry B. Neural crest cell survival is dependent on Rho kinase and is required for development of the mid face in mouse embryos. PLoS One. 2012;7(5):e37685. doi:10.1371/journal.pone.0037685.PubMedCrossRef

21.

Abe H, Kamai T, Tsujii T, Nakamura F, Mashidori T, Mizuno T, et al. Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res. 2008;29(3):155–61.PubMedCrossRef

22.

Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, Li QQ, et al. RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway. Breast Cancer Res Treat. 2011;126(3):555–63. doi:10.1007/s10549-010-0955-3.PubMedCrossRef

23.

Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, et al. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol. 2003;23(14):5043–55.PubMedCrossRef

24.

Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol. 2005;168(6):941–53. doi:10.1083/jcb.200411179.PubMedCrossRef

25.

Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389(6654):990–4. doi:10.1038/40187.PubMedCrossRef

26.

Lohn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension. 2009;54(3):676–83. doi:10.1161/HYPERTENSIONAHA.109.134353.PubMedCrossRef

27.

Hinderling PH, Karara AH, Tao B, Pawula M, Wilding I, Lu M. Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract. J Clin Pharmacol. 2007;47(1):19–25. doi:10.1177/0091270006293767.PubMedCrossRef

28.

Chen YT, Bannister TD, Weiser A, Griffin E, Lin L, Ruiz C, et al. Chroman-3-amides as potent Rho kinase inhibitors. Bioorg Med Chem Lett. 2008;18(24):6406–9. doi:10.1016/j.bmcl.2008.10.080.PubMedCrossRef

29.

Sehon CA, Wang GZ, Viet AQ, Goodman KB, Dowdell SE, Elkins PA, et al. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem. 2008;51(21):6631–4. doi:10.1021/jm8005096.PubMedCrossRef

30.

Sessions EH, Yin Y, Bannister TD, Weiser A, Griffin E, Pocas J, et al. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. Bioorg Med Chem Lett. 2008;18(24):6390–3. doi:10.1016/j.bmcl.2008.10.095.PubMedCrossRef

31.

Shahin R, Alqtaishat S, Taha MO. Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors. J Comput Aided Mol Des. 2012;26(2):249–66. doi:10.1007/s10822-011-9509-y.PubMedCrossRef

32.

Yin Y, Lin L, Ruiz C, Khan S, Cameron MD, Grant W, et al. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors. J Med Chem. 2013;56(9):3568–81. doi:10.1021/jm400062r.PubMedCrossRef

33.

Kast R, Schirok H, Figueroa-Perez S, Mittendorf J, Gnoth MJ, Apeler H, et al. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br J Pharmacol. 2007;152(7):1070–80. doi:10.1038/sj.bjp.0707484.PubMedCrossRef

34.

Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, van Goor H, et al. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol: JASN. 2008;19(11):2086–97. doi:10.1681/ASN.2007070794.PubMedCrossRef

35.

Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J Mol Cell Cardiol. 2012;52(1):83–92. doi:10.1016/j.yjmcc.2011.09.014.PubMedCrossRef

36.

Ying Z, Giachini FR, Tostes RC, Webb RC. Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation. Cardiovasc Res. 2009;83(1):155–62. doi:10.1093/cvr/cvp084.PubMedCrossRef

37.

Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science. 2003;302(5648):1215–7. doi:10.1126/science.1090154.PubMedCrossRef

38.

Fu Q, Hue J, Li S. Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition. J Neurosci: Off J Soc Neurosci. 2007;27(15):4154–64. doi:10.1523/JNEUROSCI.4353-06.2007.CrossRef

39.

Schluter T, Steinbach AC, Steffen A, Rettig R, Grisk O. Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition. Cardiovasc Res. 2008;80(2):271–9. doi:10.1093/cvr/cvn185.PubMedCrossRef

40.

Wakino S, Hayashi K, Kanda T, Tatematsu S, Homma K, Yoshioka K, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res. 2004;95(5):e45–55. doi:10.1161/01.RES.0000142313.68389.92.PubMedCrossRef

41.

Nochioka K, Tanaka S, Miura M, do Zhulanqiqige E, Fukumoto Y, Shiba N, et al. Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Circ J. 2012;76(8):2023–30.PubMedCrossRef

42.

Ghisdal P, Vandenberg G, Morel N. Rho-dependent kinase is involved in agonist-activated calcium entry in rat arteries. J Physiol. 2003;551(Pt 3):855–67. doi:10.1113/jphysiol.2003.047050.PubMedCrossRef

43.

Sakurada S, Takuwa N, Sugimoto N, Wang Y, Seto M, Sasaki Y, et al. Ca2+-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res. 2003;93(6):548–56. doi:10.1161/01.RES.0000090998.08629.60.PubMedCrossRef

44.

Fernandez-Tenorio M, Porras-Gonzalez C, Castellano A, Del Valle-Rodriguez A, Lopez-Barneo J, Urena J. Metabotropic regulation of RhoA/Rho-associated kinase by L-type Ca2+ channels: new mechanism for depolarization-evoked mammalian arterial contraction. Circ Res. 2011;108(11):1348–57. doi:10.1161/CIRCRESAHA.111.240127.PubMedCrossRef

45.

• Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Fujimura N, et al. Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens. 2011;29(2):373–9. doi:10.1097/HJH.0b013e328340902d. A clinical study that provides data indicating that CCBs inhibit ROCK activity in hypertensive patients suggesting that CCB actions are partly due to indirect ROCK inhibition.PubMedCrossRef

46.

•• Althoff TF, Juarez JA, Troidl K, Tang C, Wang S, Wirth A, et al. Procontractile G protein-mediated signaling pathways antagonistically regulate smooth muscle differentiation in vascular remodeling. J Exp Med. 2012;209(12):2277–90. doi:10.1084/jem.20120350. This study shows that signaling via the G _12/13 pathway which activates ROCK is essential for maitaining a differentiated phenotype in vascular smooth muscle cells and reduces the suceptibility to vascular injury. This is achieved by using several smooth muscle cell-specific knock out mouse models.PubMedCrossRef

47.

Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, et al. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res. 2009;104(4):531–40. doi:10.1161/CIRCRESAHA.108.188524.PubMedCrossRef

48.

Lin T, Zeng L, Liu Y, DeFea K, Schwartz MA, Chien S, et al. Rho-ROCK-LIMK-cofilin pathway regulates shear stress activation of sterol regulatory element binding proteins. Circ Res. 2003;92(12):1296–304. doi:10.1161/01.RES.0000078780.65824.8B.PubMedCrossRef

49.

• Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, Loureiro R, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010;24(9):3186–95. doi:10.1096/fj.09-145102. ROCK II is identified as an essetial part of VEGF-induced angiogenesis using hemizygous ROCK-deficient mice.PubMedCrossRef

50.

Sauzeau V, Sevilla MA, Montero MJ, Bustelo XR. The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J Clin Investig. 2010;120(1):315–30. doi:10.1172/JCI38356.PubMedCrossRef

51.

Dhaliwal JS, Casey DB, Greco AJ, Badejo Jr AM, Gallen TB, Murthy SN, et al. Rho kinase and Ca2+ entry mediate increased pulmonary and systemic vascular resistance in L-NAME-treated rats. Am J Physiol Lung Cell Mol Physiol. 2007;293(5):L1306–13. doi:10.1152/ajplung.00189.2007.PubMedCrossRef

52.

Casey DB, Badejo AM, Dhaliwal JS, Sikora JL, Fokin A, Golwala NH, et al. Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat. Am J Physiol Heart Circ Physiol. 2010;299(1):H184–92. doi:10.1152/ajpheart.00181.2009.PubMedCrossRef

53.

Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001;38(6):1307–10.PubMedCrossRef

54.

Hata T, Goto C, Soga J, Hidaka T, Fujii Y, Idei N, et al. Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis. 2011;214(1):117–21. doi:10.1016/j.atherosclerosis.2010.10.005.PubMedCrossRef

55.

• Smith CJ, Santhanam L, Alexander LM. Rho-Kinase activity and cutaneous vasoconstriction is upregulated in essential hypertensive humans. Microvasc Res. 2013;87:58–64. doi:10.1016/j.mvr.2013.02.005. The study provides direct evidence for RhoA/ROCK activation in the microvasculature of humans with high blood pressure.PubMedCrossRef

56.

Bussemaker E, Herbrig K, Pistrosch F, Palm C, Passauer J. Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients. Atherosclerosis. 2009;207(2):567–72. doi:10.1016/j.atherosclerosis.2009.05.025.PubMedCrossRef

57.

Seasholtz TM, Wessel J, Rao F, Rana BK, Khandrika S, Kennedy BP, et al. Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: role of heredity. Hypertension. 2006;47(5):937–47. doi:10.1161/01.HYP.0000217364.45622.f0.PubMedCrossRef

58.

Zhao Q, Wang L, Yang W, Chen S, Huang J, Fan Z, et al. Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population. Pharmacogenet Genomics. 2008;18(6):459–66. doi:10.1097/FPC.0b013e3282f97fb2.PubMedCrossRef

59.

Rankinen T, Church T, Rice T, Markward N, Blair SN, Bouchard C. A major haplotype block at the rho-associated kinase 2 locus is associated with a lower risk of hypertension in a recessive manner: the HYPGENE study. Hypertens Res: Off J Jpn Soc Hypertens. 2008;31(8):1651–7. doi:10.1291/hypres.31.1651.CrossRef

60.

Cavarape A, Endlich N, Assaloni R, Bartoli E, Steinhausen M, Parekh N, et al. Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol: JASN. 2003;14(1):37–45.PubMedCrossRef

61.

Roos MH, van Rodijnen WF, van Lambalgen AA, ter Wee PM, Tangelder GJ. Renal microvascular constriction to membrane depolarization and other stimuli: pivotal role for rho-kinase. Pflugers Archiv: Eur J Physiol. 2006;452(4):471–7. doi:10.1007/s00424-006-0053-x.CrossRef

62.

Inscho EW, Cook AK, Webb RC, Jin LM. Rho-kinase inhibition reduces pressure-mediated autoregulatory adjustments in afferent arteriolar diameter. Am J Physiol Ren Physiol. 2009;296(3):F590–7. doi:10.1152/ajprenal.90703.2008.CrossRef

63.

Grisk O, Schluter T, Reimer N, Zimmermann U, Katsari E, Plettenburg O, et al. The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012;30(5):980–9. doi:10.1097/HJH.0b013e328351d459.PubMedCrossRef

64.

Liu Y, Echtermeyer F, Thilo F, Theilmeier G, Schmidt A, Schulein R, et al. The proteoglycan syndecan 4 regulates transient receptor potential canonical 6 channels via RhoA/Rho-associated protein kinase signaling. Arterioscler Thromb Vasc Biol. 2012;32(2):378–85. doi:10.1161/ATVBAHA.111.241018.PubMedCrossRef

65.

Eisen R, Walid S, Ratcliffe DR, Ojakian GK. Regulation of epithelial tubule formation by Rho family GTPases. Am J Physiol Cell Physiol. 2006;290(5):C1297–309. doi:10.1152/ajpcell.00287.2005.PubMedCrossRef

66.

Szaszi K, Sirokmany G, Di Ciano-Oliveira C, Rotstein OD, Kapus A. Depolarization induces Rho-Rho kinase-mediated myosin light chain phosphorylation in kidney tubular cells. Am J Physiol Cell Physiol. 2005;289(3):C673–85. doi:10.1152/ajpcell.00481.2004.PubMedCrossRef

67.

•• Ramseyer VD, Hong NJ, Garvin JL. Tumor necrosis factor alpha decreases nitric oxide synthase type 3 expression primarily via Rho/Rho kinase in the thick ascending limb. Hypertension. 2012;59(6):1145–50. doi:10.1161/HYPERTENSIONAHA.111.189761. The study shows that RhoA/ROCK mediate downregulation of eNOS (NOS3) in isolated rat thick ascending limb suggesting that this pathway could be involved in renal tubular sodium retention.PubMedCrossRef

68.

Li W, Zhang Y, Bouley R, Chen Y, Matsuzaki T, Nunes P, et al. Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of Rho GTPase. Am J Physiol Ren Physiol. 2011;301(2):F309–18. doi:10.1152/ajprenal.00001.2011.CrossRef

69.

Grisk O, Packebusch M, Steinbach AC, Schluter T, Kopp UC, Rettig R. Endothelin-1-induced activation of rat renal pelvic contractions depends on cyclooxygenase-1 and Rho kinase. Am J Physiol Regul Integr Comp Physiol. 2010;299(6):R1602–9. doi:10.1152/ajpregu.00452.2010.PubMedCrossRef

70.

Nishikimi T, Koshikawa S, Ishikawa Y, Akimoto K, Inaba C, Ishimura K, et al. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens. 2007;25(5):1053–63. doi:10.1097/HJH.0b013e3280825440.PubMedCrossRef

71.

Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension. 2006;47(6):1075–83. doi:10.1161/01.HYP.0000221605.94532.71.PubMedCrossRef

72.

• Williams JM, Johnson AC, Stelloh C, Dreisbach AW, Franceschini N, Regner KR, et al. Genetic variants in Arhgef11 are associated with kidney injury in the Dahl salt-sensitive rat. Hypertension. 2012;60(5):1157–68. doi:10.1161/HYPERTENSIONAHA.112.199240. Using congenic rat lines the authors identify a Rho guanine nucleotide exchange factor gene of Dahl-S rats as cause of increased susceptibility to hypertensive renal disease.PubMedCrossRef

73.

Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension. 2005;45(4):538–44. doi:10.1161/01.HYP.0000157408.43807.5a.PubMedCrossRef

74.

Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. J Hypertens. 2008;26(9):1837–48. doi:10.1097/HJH.0b013e328305086c.PubMedCrossRef

75.

Komers R, Oyama TT, Beard DR, Anderson S. Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats. Br J Pharmacol. 2011;162(1):163–74. doi:10.1111/j.1476-5381.2010.01031.x.PubMedCrossRef

76.

Mustafa S, Vasudevan H, Yuen VG, McNeill JH. Renal expression of arachidonic acid metabolizing enzymes and RhoA/Rho kinases in fructose insulin resistant hypertensive rats. Mol Cell Biochem. 2010;333(1–2):203–9. doi:10.1007/s11010-009-0220-4.PubMedCrossRef

77.

Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2(5). doi:10.1136/bmjopen-2012-001007.

78.

Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacol Ther. 2013;139(1):51–9. doi:10.1016/j.pharmthera.2013.04.003.PubMedCrossRef

79.

Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55(3):619–26. doi:10.1161/HYPERTENSIONAHA.109.140665.PubMedCrossRef

80.

Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976–82. doi:10.1161/CIRCULATIONAHA.112.130880.PubMedCrossRef

81.

Ito K, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H, et al. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res. 2003;92(12):1337–43. doi:10.1161/01.RES.0000079941.59846.D4.PubMedCrossRef

82.

Ito K, Hirooka Y, Sagara Y, Kimura Y, Kaibuchi K, Shimokawa H, et al. Inhibition of Rho-kinase in the brainstem augments baroreflex control of heart rate in rats. Hypertension. 2004;44(4):478–83. doi:10.1161/01.HYP.0000143120.24612.68.PubMedCrossRef

83.

Sagara Y, Hirooka Y, Nozoe M, Ito K, Kimura Y, Sunagawa K. Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptors. J Hypertens. 2007;25(2):399–406. doi:10.1097/HJH.0b013e328010b87f.PubMedCrossRef

84.

Kumai T, Takeba Y, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, et al. Fasudil attenuates sympathetic nervous activity in the adrenal medulla of spontaneously hypertensive rats. Life Sci. 2007;81(15):1193–8. doi:10.1016/j.lfs.2007.08.008.PubMedCrossRef

85.

Thoenen H, Mueller RA, Axelrod J. Trans-synaptic induction of adrenal tyrosine hydroxylase. J Pharmacol Exp Ther. 1969;169(2):249–54.PubMed

86.

Satoh N, Toyohira Y, Itoh H, Zhang H, Ueno S, Tsutsui M, et al. Stimulation of norepinephrine transporter function by fasudil, a Rho kinase inhibitor, in cultured bovine adrenal medullary cells. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(9):921–31. doi:10.1007/s00210-012-0773-8.PubMedCrossRef

Title: Potential Benefits of Rho-kinase Inhibition in Arterial Hypertension
Author: Olaf Grisk
Publication date: 01-10-2013
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 5/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-013-0373-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Sodium Intake and Blood Pressure in Children

Blockade of the Renin-Angiotensin System in Hypertensive Patients with Atherosclerotic Renal Artery Stenosis

Left Ventricular Hypertrophy in Hypertensive Children and Adolescents: Predictors and Prevalence

Endothelin Antagonism and Its Role in the Treatment of Hypertension

Primary Hypertension in Childhood

Hypertension after Kidney Transplantation: A Pathophysiologic Approach

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage